Lenacapavir is used for treating heavily treatment-experienced adults with multidrug-resistant HIV, always with other medications, and for preventing HIV (PrEP) in at-risk individuals, always combined with safer sex practices like condoms, offering long-acting, twice-yearly injections after initial oral doses. Its unique capsid inhibitor action targets the HIV virus’s shell, preventing replication, and it’s administered by a healthcare professional. Its therapeutic use is listed as antivirals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Yeztugo and GS-CA2. Its PubChem CID is 133082658.
Lenacapavir
| CAS No | 2189684-44-2 |
|---|---|
| Molecular Formula | C39H32ClF10N7O5S2 |
| Molecular Weight | 968.30 g/mol |
| Synonyms | N-[(1S)-1-[3-[4-chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)indazol-7-yl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)pyridin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2S,4R)-5,5-difluoro-9-(trifluoromethyl)-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Lenacapavir is used for treating heavily treatment-experienced adults with multidrug-resistant HIV, always with other medications, and for preventing HIV (PrEP) in at-risk individuals, always combined with safer sex practices like condoms, offering long-acting, twice-yearly injections after initial oral doses.
The listed CAS number is 2189684-44-2.
The listed molecular formula is C39H32ClF10N7O5S2.
The listed molecular weight is 968.30 g/mol.
N-[(1S)-1-[3-[4-chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)indazol-7-yl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)pyridin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2S,4R)-5,5-difluoro-9-(trifluoromethyl)-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetamide.
The source lists Yeztugo and GS-CA2.